<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Orphanet J Rare Dis</journal-id><journal-title>Orphanet Journal of Rare Diseases</journal-title><issn pub-type="epub">1750-1172</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1750-1172-4-12</article-id><article-id pub-id-type="pmid">19368725</article-id><article-id pub-id-type="doi">10.1186/1750-1172-4-12</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Screening for Alpha 1 antitrypsin deficiency in Tunisian subjects with obstructive lung disease: a feasibility report</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Denden</surname><given-names>Sabri</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>denden_sabri@yahoo.fr</email></contrib><contrib id="A2" corresp="yes" contrib-type="author"><name><surname>Zorzetto</surname><given-names>Michele</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>m.zorzetto@smatteo.pv.it</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Amri</surname><given-names>Fethi</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>fethi.amri@rns.tn</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Knani</surname><given-names>Jalel</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>knani_jalel@yahoo.fr</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Ottaviani</surname><given-names>Stefania</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>ste13otta@yahoo.com</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Scabini</surname><given-names>Roberta</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>roberta_scabini@hotmail.com</email></contrib><contrib id="A7" contrib-type="author"><name><surname>Gorrini</surname><given-names>Marina</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>m.gorrini@smatteo.pv.it</email></contrib><contrib id="A8" contrib-type="author"><name><surname>Ferrarotti</surname><given-names>Ilaria</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>i.ferrarotti@smatteo.pv.it</email></contrib><contrib id="A9" contrib-type="author"><name><surname>Campo</surname><given-names>Ilaria</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>i.campo@smatteo.pv.it</email></contrib><contrib id="A10" contrib-type="author"><name><surname>Chibani</surname><given-names>Jemni Ben</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>jemni.BenChibani@fphm.rnu.tn</email></contrib><contrib id="A11" contrib-type="author"><name><surname>Khelil</surname><given-names>Amel Haj</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>Amel.HK@fsm.rnu.tn</email></contrib><contrib id="A12" contrib-type="author"><name><surname>Luisetti</surname><given-names>Maurizio</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>m.luisetti@smatteo.pv.it</email></contrib></contrib-group><aff id="I1"><label>1</label>Biochemistry and Molecular Biology Laboratory, Faculty of Pharmacy, AV. Avicienne 1, 5019 Monastir, Tunisia</aff><aff id="I2"><label>2</label>Center for Diagnosis of Inherited Alpha1-antirtypsin Deficiency, Institute for Respiratory Disease, IRCCS San Matteo Hospital Foundation, Piazza Golgi 19, 27100 Pavia, Italy</aff><aff id="I3"><label>3</label>Pediatric Department, Ibn El Jazzar Hospital, Av Ibn El Jazzar, 3100 Kairouan, Tunisia</aff><aff id="I4"><label>4</label>Pulmonology Department, CHU Tahar Sfar, 5111 Mahdia, Tunisia</aff><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>15</day><month>4</month><year>2009</year></pub-date><volume>4</volume><fpage>12</fpage><lpage>12</lpage><ext-link ext-link-type="uri" xlink:href="http://www.ojrd.com/content/4/1/12"/><history><date date-type="received"><day>27</day><month>11</month><year>2008</year></date><date date-type="accepted"><day>15</day><month>4</month><year>2009</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2009 Denden et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>Denden et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Denden Sabri denden_sabri@yahoo.fr </dc:author><dc:title> Screening for Alpha 1 antitrypsin deficiency in Tunisian subjects with obstructive lung disease: a feasibility report </dc:title><dc:date>2009</dc:date><dcterms:bibliographicCitation>Orphanet Journal of Rare Diseases 4(1): 12-. (2009)</dcterms:bibliographicCitation><dc:identifier type="sici">1750-1172(2009)4:1&#x0003c;12&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1750-1172</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>AATD is one of the most common inherited disorders in the World. However, it is generally accepted that AATD in North African populations is not a risk factor for lung and/or liver disease, based on a number of small studies. We therefore planned a screening study for detection of AATD in patients with OLD in a cohort of patients from Kairouan in central Tunisia. Methods: One hundred twenty patients with OLD (asthma, emphysema, COPD) were enrolled in the screening programme. Laboratory diagnosis for AATD was performed according to current diagnostic standards.</p></sec><sec><title>Results</title><p>We found that 6/120 OLD patients carried an AAT deficient allele, 1 PI*MZ, 1 PI*MPlowel, 3 PI*MMmalton, 1 PI*MMwurzburg.</p></sec><sec><title>Conclusion</title><p>this pilot study demonstrated that alleles related to deficiency of AAT are not absent in the Tunisian population, and that rare AATD variants prevailed over commonest PI*Z variant. These results would support a larger scale screening for AATD in Tunisia.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Alpha 1 antitrypsin (AAT) is an acute phase glycoprotein predominantly derived from the liver, and its major biological function is to inhibit neutrophil elastase [<xref ref-type="bibr" rid="B1">1</xref>]. AAT, a highly polymorphic protein with more than 120 variants known to date [<xref ref-type="bibr" rid="B2">2</xref>] is coded by a gene, called <italic>SERPINA1</italic>, located on chromosome 14q31-32.3 within the SERPIN cluster [<xref ref-type="bibr" rid="B3">3</xref>]. The <italic>SERPINA1 </italic>PI*M alleles code for the commonest normal AAT variants, whereas PI*S and PI*Z are the most common deficiency alleles associated with reduced concentrations of plasma AAT. Nevertheless, there are at least 30 <italic>SERPINA1 </italic>alleles rarely detected, other than the PI*Z and the PI*S alleles, which are associated with significantly reduced AAT levels [<xref ref-type="bibr" rid="B4">4</xref>-<xref ref-type="bibr" rid="B6">6</xref>].</p><p>Inherited deficiency of AAT (AATD) is one of the most common genetic disorders in the world, and is associated with an increased risk of developing lung and, to a lesser extent, liver disease [<xref ref-type="bibr" rid="B7">7</xref>]. Individuals homozygous for the PI*Z allele usually have an AAT level in the region of 0.35 g/L [<xref ref-type="bibr" rid="B3">3</xref>] and are at high risk for the development of emphysema [<xref ref-type="bibr" rid="B8">8</xref>], asthma [<xref ref-type="bibr" rid="B9">9</xref>], chronic bronchitis and bronchiectasis [<xref ref-type="bibr" rid="B10">10</xref>]. However, heterozygous individuals with PI*S and PI*Z mutation (or rare mutations) showing a more protective AAT level (&#x0003e; 0,8 g/L) [<xref ref-type="bibr" rid="B3">3</xref>] can also be at increased risk for lung disease, depending on multiple environmental factors, such as smoking, occupational exposure, and environmental exposure.</p><p>Epidemiology studies showed that highest prevalence of PI*ZZ related AATD is recorded among Northern Europeans and populations with North European background [<xref ref-type="bibr" rid="B11">11</xref>]. Notwithstanding, during the last few years, based on estimates from allele frequencies obtained in available cohort studies, it has been suggested that the Z variant is not only common in Caucasians, but also among other ethnic groups worldwide [<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B13">13</xref>].</p><p>A total of 30 cohorts have been investigated for AATD in the African continent. Twenty four cohorts, having a total of 4,718 individuals, were in Sub-Saharian Africa [<xref ref-type="bibr" rid="B14">14</xref>], 6 cohorts with a total sample size of 1,735 have been investigated in the north African populations [<xref ref-type="bibr" rid="B15">15</xref>-<xref ref-type="bibr" rid="B20">20</xref>], Three of them in Tunisia: in the Tunisian population, the PI*Z allele, previously considered as virtually absent [<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B16">16</xref>], has then been detected once on the heterozygous state in a total cohort of 1,168 individuals (allele frequency 0.04%) [<xref ref-type="bibr" rid="B17">17</xref>]. However, none of the previous surveys in Tunisia has looked at rare, non-S and non-Z SERPINA1 variants, which have been hypothesised to be particularly frequent in the Mediterrenean area, where PI*Z allele frequency is reduced [<xref ref-type="bibr" rid="B4">4</xref>]. We therefore aimed this paper at investigating AATD variants in a Tunisia area, targeting a cohort of obstructed individuals, in which the diagnosis of AATD has been recommended accoding to the ATS/ERS document [<xref ref-type="bibr" rid="B21">21</xref>].</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Study subjects</title><p>Upon approval by the local Ethical Committee, patients with obstructive lung disease (OLD: asthma, emphysema, COPD), referred to the pulmonary disease department in Kairouan regional hospital (central Tunisia) from June 2006 to September 2006, were enrolled in the screening programme. Diagnosis of obstructive lung disease was obtained by symptoms, radiology, lung function examinations and allergy history.</p></sec><sec><title>Quantitative determination of AAT level</title><p>AAT concentration measurement was performed on plasma samples with a rate immune turbidimetric method (Konelab 20, Thermo Clinical Labsystem, Finland), using a polyclonal anti-human AAT antibody (Thermo Electron Corporation, Finland). A calibrator (Specical, Thermo Electron Corporation, Finland) with an assigned AAT value was used as a standard. A control (Specitrol, Thermo Electron Corporation, Finland) with an assigned AAT value was used after a predefined reaction number. Plasma samples for the turbidimetric assay are diluted by the instrument 1:10 (AAT reading range, 0.23&#x02013;4.4 g/L). The turbidimetry of antigen-antibody complex was measured at 360 nm. Values obtained are regressed according to the calibration curve, and expressed as g/L.</p></sec><sec><title>Molecular diagnosis of AATD</title><p>DNA extracted from the white blood cells of all subjects by standard methods, was submitted to genotyping for Z and S <italic>SERPINA1 </italic>alleles, by PCR-RFLP, as previously described [<xref ref-type="bibr" rid="B22">22</xref>]. According to published diagnostic algorythm [<xref ref-type="bibr" rid="B23">23</xref>], samples negative for Z and S alleles, but with inconsistent AAT level/genotype were submitted to sequencing of <italic>SERPINA1</italic>exons II, III, IV, and V, as previously described [<xref ref-type="bibr" rid="B24">24</xref>].</p></sec></sec><sec><title>Results</title><p>One hundred twenty subjects with OLD were enroled in this study. There were 115 males and 5 females, mean age (SD) 49.2 (9.5) years (range 34&#x02013;81). The large majority of patients were smokers (84.1%). As far as the OLD phenotype was concerned, there were 49 COPD (40.8%), 48 emphysema (40%), and 23 asthma patients (19.2%). Mean (SD) plasma AAT level was 1.74 g/L (0.63) (range 0.81 to 3.3). Plasma AAT level distribution is shown in figure <xref ref-type="fig" rid="F1">1</xref>.</p><fig position="float" id="F1"><label>Figure 1</label><caption><p><bold>AAT plasma level distribution in OLD patients</bold>. The expected normal values (in green) were calculated using Rankit proportional estimation.</p></caption><graphic xlink:href="1750-1172-4-12-1"/></fig><p><italic>SERPINA1 </italic>S and Z allele genotyping, performed in all OLD subjects, allowed the detection of one PI*MZ individual (plasma AAT level: 0.81 g/l, consistent with the detected genotype).</p><p>Nevertheless, some subjects negative for PI*S and PI*Z allele detection, displayed plasma AAT levels consistent with intermediate AATD; in particular, 4 subjects displayed plasma AAT level &#x0003c; 1 g/L [mean (SD) 0.91 g/L (0.02)]. According to our protocol for detection of rare AATD variants, such samples with inconsistent AAT level/genotype were suitable for sequencing [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B24">24</xref>]. In the absence of reference values of plasma AAT in the general population from Tunisia, we decided to submit to sequencing, DNA samples from subjects with plasma AAT levels &#x0003c; 1.5 g/L, rather than the usual cut-off of 1.13 g/L [<xref ref-type="bibr" rid="B25">25</xref>]. We therefore sequenced 24 DNA samples (plasma AAT level range: 0.89&#x02013;1.48). We found that 5 subjects were heterozygous for rare deficiency variants: 3 subjects carried the PI* MMmalton, 1 the PI*MPlowell, and 1 the PI*MMwurzburg genotypes. Figure <xref ref-type="fig" rid="F2">2</xref> summarises the results of genotyping/sequencing.</p><fig position="float" id="F2"><label>Figure 2</label><caption><p><bold>Schematic representation of the genotyping/sequencing results</bold>.</p></caption><graphic xlink:href="1750-1172-4-12-2"/></fig></sec><sec><title>Discussion</title><p>Meta-analysis of available data showed that <italic>SERPINA 1 </italic>PI*S and PI*Z deficiency alleles are extremely rare in North African populations [<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B13">13</xref>]. Recent investigations in the Tunisian population confirmed the low frequency of AATD common deficiency variants in the general population and healthy subjects (1078 subjects investigated: 15 PI*MS detected (PI*S: 0.7%; PI*Z: 0%)) [<xref ref-type="bibr" rid="B15">15</xref>-<xref ref-type="bibr" rid="B17">17</xref>], as well as in COPD patients (90 subjects investigated: 1 PI*SS and 1 PI*MZ detected (PI*S: 1%; PI*Z: 0.5%)) [<xref ref-type="bibr" rid="B17">17</xref>]. The present study, performed in 120 patients with OLD, confirms these data: PI*S allele was not seen, whereas PI*Z was detected only once on the heterozygous state (frequency 0.4%).</p><p>In this study, we extended the <italic>SERPINA1 </italic>gene investigation to variants not detectable by rapid PI*S and PI*Z genotyping: by this strategy, we found 5 more deficiency variants (frequency as a whole 2%) detected on the heterozygous state. Such a condition of a relatively higher frequency of rare than common AATD variants, is shared by Central &#x02013; Southern regions of Italy, in which PI*Mmalton and PI*Mprocida variants seem to prevail over PI*Z [<xref ref-type="bibr" rid="B4">4</xref>]. Interestingly, the PI*Mmalton variant, detected in three unrelated individuals in this paper, is the commonest AATD variant in Sardinia, where the PI*Z variant is detected very rarely [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B26">26</xref>]. A novel <italic>SERPINA1 </italic>Null mutation, first described in an Egyptian family, and for that reason called Q0*cairo [<xref ref-type="bibr" rid="B27">27</xref>] has been repeatedly detected in unrelated individuals from regions of Southern Italy. Population admixture due to migration occurred in ancestral periods, as well as contacts for commercial purposes in more recent centuries are likely to be responsible for dissemination of rare AATD variants in the Southern Mediterrenean basin. Table <xref ref-type="table" rid="T1">1</xref> summarizes the rare variants reported in the Mediterranean basin, as well as the mutations types, the cellular defect and the related clinical data [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B28">28</xref>-<xref ref-type="bibr" rid="B30">30</xref>].</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Rare AATD variants reported in the Mediterranean basin, type of mutation involved, cellular defect and the related clinical data.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>PI allele</bold></td><td align="left"><bold>Mutation type</bold></td><td align="left"><bold>Cellular defect</bold></td><td align="left"><bold>Associated disease</bold></td></tr></thead><tbody><tr><td align="left">M<sub>malton</sub></td><td align="left">3 bp deletion</td><td align="left">intracellular aggregation</td><td align="left">lung, liver</td></tr><tr><td align="left">M<sub>procida</sub></td><td align="left">1 bp substitution</td><td align="left">intracellular degradation</td><td align="left">lung</td></tr><tr><td align="left">P<sub>lowell</sub></td><td align="left">1 bp substitution</td><td align="left">intracellular degradation</td><td align="left">lung</td></tr><tr><td align="left">I</td><td align="left">1 bp substitution</td><td align="left">intracellular aggregation</td><td align="left">lung, liver</td></tr><tr><td align="left">M<sub>varallo</sub></td><td align="left">30 bp deletion/22-bp insertion</td><td align="left">unkown</td><td align="left">lung</td></tr><tr><td align="left">M<sub>heerlen</sub></td><td align="left">1 bp substitution</td><td align="left">intracellular degradation</td><td align="left">lung</td></tr><tr><td align="left">M<sub>wurzburg</sub></td><td align="left">1 bp substitution</td><td align="left">intracellular aggregation</td><td align="left">lung</td></tr><tr><td align="left">Q0<sub>isola di procida</sub></td><td align="left">17 kb deletion</td><td align="left">no mRNA</td><td align="left">lung</td></tr><tr><td align="left">Q0<sub>clayton</sub></td><td align="left">1 bp insertion</td><td align="left">truncated protein</td><td align="left">lung</td></tr><tr><td align="left">Q0<sub>cairo</sub></td><td align="left">1 bp substitution</td><td align="left">unkown</td><td align="left">lung</td></tr><tr><td align="left">Y<sub>barcelona</sub></td><td align="left">2 substitutions of 1 bp</td><td align="left">unkown</td><td align="left">lung</td></tr><tr><td align="left">Q0<sub>lisbon</sub></td><td align="left">1 bp substitution</td><td align="left">unkown</td><td align="left">lung</td></tr><tr><td align="left">M<sub>vall d'hebron</sub></td><td align="left">1 bp substitution</td><td align="left">unkown</td><td align="left">lung</td></tr></tbody></table></table-wrap><p>This study strengthens the concept that for a correct laboratory diagnosis of AATD, there is a need of a combination of biochemical and biomolecular methods [<xref ref-type="bibr" rid="B24">24</xref>], otherwise rare AATD variants will be missed [<xref ref-type="bibr" rid="B5">5</xref>]. These preliminary data also confirm the usefulness of enrolling patients with OLD in a screening programme for AATD. According to the ATS/ERS statement's evidence based recommendations, all subjects with COPD and asthma should be submitted to diagnostic testing for AATD [<xref ref-type="bibr" rid="B21">21</xref>]. In this paper, although no subjects with severe AATD deficiency were detected, we found six out of 120 subjects (5%) carrying the so called "intermediate deficiency", that means heterozygosity with one normal PI*M allele and one severe AATD allele [mean (SD) plasma AAT level: 0.93 g/L (0.12)]. These findings are consistent with the hypothesis that intermediate AATD, such as PI*MZ or equivalent genotypes, represent a risk factor for developing COPD [<xref ref-type="bibr" rid="B20">20</xref>]. Recent meta-analysis [<xref ref-type="bibr" rid="B31">31</xref>] reported the increase in risk of COPD in PI*MZ heterozygous individuals (OR for PI*MZ versus PI*MM (normal genotype) was 2.31 (95% CI 1.60 to 3.35)).</p><p>Severe AATD diagnosis in the North African countries might be beneficial to the treatment of patients with the introduction of AAT replacement therapy in these populations. Furthermore, AATD carrier diagnosis might provide genetic counseling to persons who are planning a pregnancy or are in the prenatal period [<xref ref-type="bibr" rid="B21">21</xref>]. In addition, awareness of carrying a gene that may increase the susceptibility to COPD may be an additional factor for a successful enrolment of patients in smoking cessation programmes [<xref ref-type="bibr" rid="B32">32</xref>].</p></sec><sec><title>Conclusion</title><p>This investigation, performed for the first time with current diagnostic standards in a North African population, highlights the implication of AATD in development of OLD in this area, whereas previous data excluded a role for AATD in the African continent. This would suggest that, similarly to what happens in the Caucasians, also in Northern Africans AATD is an underdiagnosed condition, and therefore investigations in larger sample sizes would be advisable. It seems also likely that targeted detection strategy to identify affected individuals produces a rate of detecting disease higher than the population-based screening programs. Such approach may also contribute to change the widespread concept concerning the AAT deficiency epidemiology in North African and others populations.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>SD, MZ, IF and IC designed the study and drafted the Manuscript. FA and JK participated in data collection. SO, RS and MG participated in laboratory investigations. JBC, AHK and ML supervised the study process, revised and edited the final manuscript.</p></sec></body><back><ack><sec><title>Acknowledgements</title><p>SD was supported by a Short Term Training Fellowship (n&#x000b0; 721) from European Respiratory Society. The diagnostic center for AATD in Pavia gratefully acknoweledges the support from Fondazione IRCCCS Policlinico San Matteo, Ricerca Corrente programs, and from Talecris Biotherapeutics, Germany.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lomas</surname><given-names>DA</given-names></name><name><surname>Parfrey</surname><given-names>H</given-names></name></person-group><article-title>Alpha 1 Antitrypsin deficiency 4: molecular pathophysiology</article-title><source>Thorax</source><year>2004</year><volume>59</volume><fpage>529</fpage><lpage>535</lpage><pub-id pub-id-type="pmid">15170041</pub-id><pub-id pub-id-type="doi">10.1136/thx.2003.006528</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>DeMeo</surname><given-names>DL</given-names></name><name><surname>Silverman</surname><given-names>EK</given-names></name></person-group><article-title>Alpha 1 antitrypsin deficiency. 2: genetic aspects of alpha 1 antitrypsin deficiency: phenotypes and genetic modifiers of emphysema risk</article-title><source>Thorax</source><year>2004</year><volume>59</volume><fpage>259</fpage><lpage>264</lpage><pub-id pub-id-type="pmid">14985567</pub-id><pub-id pub-id-type="doi">10.1136/thx.2003.006502</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Crystal</surname><given-names>RG</given-names></name></person-group><article-title>&#x003b1;1-antitrypsin Deficiency, emphysema, and liver disease genetic basis and strategies for therapy</article-title><source>J Clin Invest</source><year>1990</year><volume>85</volume><fpage>1343</fpage><lpage>1352</lpage><pub-id pub-id-type="pmid">2185272</pub-id><pub-id pub-id-type="doi">10.1172/JCI114578</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ferrarotti</surname><given-names>I</given-names></name><name><surname>Baccheschi</surname><given-names>J</given-names></name><name><surname>Zorzetto</surname><given-names>M</given-names></name><name><surname>Tinelli</surname><given-names>C</given-names></name><name><surname>Corda</surname><given-names>L</given-names></name><name><surname>Balbi</surname><given-names>B</given-names></name><etal></etal></person-group><article-title>Prevalence and phenotype of subjects carrying rare variants in the Italian registry for alpha1-antitrypsin deficiency</article-title><source>J Med Genet</source><year>2005</year><volume>42</volume><fpage>282</fpage><lpage>287</lpage><pub-id pub-id-type="pmid">15744045</pub-id><pub-id pub-id-type="doi">10.1136/jmg.2004.023903</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Prins</surname><given-names>J</given-names></name><name><surname>Mejiden</surname><given-names>BB van der</given-names></name><name><surname>Kraaijenhagen</surname><given-names>RJ</given-names></name><name><surname>Wielders</surname><given-names>JPM</given-names></name></person-group><article-title>Inherited obstructive pulmonary disease: new selective sequencing workup for &#x003b1;1-antitrypsin deficiency identified two previously unidentified Null allels</article-title><source>Clin Chem</source><year>2008</year><volume>51</volume><fpage>101</fpage><lpage>107</lpage><pub-id pub-id-type="pmid">18024524</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fregonese</surname><given-names>L</given-names></name><name><surname>Stolk</surname><given-names>J</given-names></name><name><surname>Frants</surname><given-names>RR</given-names></name><name><surname>Veldhuisen</surname><given-names>B</given-names></name></person-group><article-title>Alpha1 antitrypsin Null mutations and severity of emphysema</article-title><source>Respir Med</source><year>2008</year><volume>102</volume><fpage>876</fpage><lpage>884</lpage><pub-id pub-id-type="pmid">18353624</pub-id><pub-id pub-id-type="doi">10.1016/j.rmed.2008.01.009</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stolk</surname><given-names>J</given-names></name><name><surname>Seersholm</surname><given-names>N</given-names></name><name><surname>Kalsheker</surname><given-names>N</given-names></name></person-group><article-title>Alpha1-antitrypsin deficiency: current perspective on research, diagnosis, and management</article-title><source>Int J COPD</source><year>2006</year><volume>1</volume><fpage>151</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.2147/copd.2006.1.2.151</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Laurell</surname><given-names>CB</given-names></name><name><surname>Eriksson</surname><given-names>S</given-names></name></person-group><article-title>The electrophoretic alpha 1-globulin pattern of serum in alpha 1-antitrypsin deficiency</article-title><source>Scand J Clin Lab Invest</source><year>1963</year><volume>15</volume><fpage>132</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.3109/00365516309051324</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eden</surname><given-names>E</given-names></name><name><surname>Hammel</surname><given-names>J</given-names></name><name><surname>Rouhani</surname><given-names>FN</given-names></name><name><surname>Brantly</surname><given-names>ML</given-names></name><name><surname>Barker</surname><given-names>AF</given-names></name><name><surname>Buist</surname><given-names>AS</given-names></name><etal></etal></person-group><article-title>Asthma features in severe alpha1-antitrypsin deficiency: experience of the National Heart, Lung, and Blood Institute Registry</article-title><source>Chest</source><year>2003</year><volume>123</volume><fpage>765</fpage><lpage>771</lpage><pub-id pub-id-type="pmid">12628876</pub-id><pub-id pub-id-type="doi">10.1378/chest.123.3.765</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dowson</surname><given-names>LJ</given-names></name><name><surname>Guest</surname><given-names>PJ</given-names></name><name><surname>Stockley</surname><given-names>RA</given-names></name></person-group><article-title>The relationship of chronic sputum expectoration to physiologic, radiologic, and health status characteristics in alpha(1)-antitrypsin deficiency (Pi Z)</article-title><source>Chest</source><year>2002</year><volume>122</volume><fpage>1247</fpage><lpage>1255</lpage><pub-id pub-id-type="pmid">12377849</pub-id><pub-id pub-id-type="doi">10.1378/chest.122.4.1247</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Luisetti</surname><given-names>M</given-names></name><name><surname>Seersholm</surname><given-names>N</given-names></name></person-group><article-title>Alpha1-antitrypsin Deficiency. 1: Epidemiology of Alpha1-antitrypsin deficiency</article-title><source>Thorax</source><year>2004</year><volume>59</volume><fpage>164</fpage><lpage>169</lpage><pub-id pub-id-type="pmid">14760160</pub-id><pub-id pub-id-type="doi">10.1136/thorax.2003.006494</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Serres</surname><given-names>FJ</given-names></name></person-group><article-title>Worldwide racial and ethnic distribution of &#x003b1;1-antitrypsin deficiency. Summary of an analysis of published genetic epidemiology surveys</article-title><source>Chest</source><year>2002</year><volume>122</volume><fpage>1818</fpage><lpage>1829</lpage><pub-id pub-id-type="pmid">12426287</pub-id><pub-id pub-id-type="doi">10.1378/chest.122.5.1818</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Serres</surname><given-names>FJ</given-names></name><name><surname>Blanco</surname><given-names>I</given-names></name><name><surname>Fern&#x000e1;ndez-Bustillo</surname><given-names>E</given-names></name></person-group><article-title>PI S and PI Z Alpha-1 antitrypsin deficiency worldwide. A review of existing genetic epidemiological data</article-title><source>Monaldi Arch Chest Dis</source><year>2007</year><volume>67</volume><fpage>184</fpage><lpage>208</lpage><pub-id pub-id-type="pmid">18309698</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Serres</surname><given-names>FJ</given-names></name><name><surname>Blanco</surname><given-names>I</given-names></name><name><surname>Fern&#x000e1;ndez-Bustillo</surname><given-names>E</given-names></name></person-group><article-title>Health implications of alpha1-antitrypsin deficiency in Sub-Sahara African countries and their emigrants in Europe and the New World</article-title><source>Genet Med</source><year>2005</year><volume>7</volume><fpage>175</fpage><lpage>184</lpage><pub-id pub-id-type="pmid">15775753</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Makni</surname><given-names>S</given-names></name><name><surname>Zitouni</surname><given-names>M</given-names></name><name><surname>Ayed</surname><given-names>K</given-names></name><name><surname>Mhirii</surname><given-names>S</given-names></name><name><surname>Azabi</surname><given-names>S</given-names></name><name><surname>Cherif</surname><given-names>F</given-names></name><etal></etal></person-group><article-title>Absence of the alpha 1 antitrypsin PiZ allele in Tunisia substantiates the particular genetic structure of African populations</article-title><source>Am J Hum Biol</source><year>1997</year><volume>9</volume><fpage>223</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1520-6300(1997)9:2&#x0003c;223::AID-AJHB8&#x0003e;3.0.CO;2-0</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chaabani</surname><given-names>H</given-names></name><name><surname>Martin</surname><given-names>JP</given-names></name><name><surname>Frants</surname><given-names>RR</given-names></name><name><surname>Lefranc</surname><given-names>G</given-names></name></person-group><article-title>Genetic study of Tunisian Berber. Alpha 1 antitrypsin (Pi) polymorphism. Report of a new allele (Pi S berber)</article-title><source>Exp Clin Immunogenet</source><year>1984</year><volume>1</volume><fpage>19</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">6400989</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Denden</surname><given-names>S</given-names></name><name><surname>Haj Khelil</surname><given-names>A</given-names></name><name><surname>Perrin</surname><given-names>P</given-names></name><name><surname>Daimi</surname><given-names>H</given-names></name><name><surname>Leban</surname><given-names>N</given-names></name><name><surname>Ouaja</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Alpha 1 antitrypsin polymorphism in the Tunisian population with special reference to pulmonary disease</article-title><source>Pathol Biol</source><year>2008</year><volume>56</volume><fpage>106</fpage><lpage>110</lpage><pub-id pub-id-type="pmid">18031952</pub-id><pub-id pub-id-type="doi">10.1016/j.patbio.2007.05.003</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ezzikouri</surname><given-names>S</given-names></name><name><surname>El Feidi</surname><given-names>AE</given-names></name><name><surname>El Kihal</surname><given-names>L</given-names></name><name><surname>Afifi</surname><given-names>R</given-names></name><name><surname>Bennazzouz</surname><given-names>R</given-names></name><name><surname>Hassar</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Prevalence of common HFE and SERPINA1 mutations in patients with hepatocellular carcinoma in a Moroccan population</article-title><source>Arch Med Res</source><year>2008</year><volume>39</volume><fpage>236</fpage><lpage>241</lpage><pub-id pub-id-type="pmid">18164971</pub-id><pub-id pub-id-type="doi">10.1016/j.arcmed.2007.09.006</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Harich</surname><given-names>N</given-names></name><name><surname>Esteban</surname><given-names>E</given-names></name><name><surname>Chafic</surname><given-names>A</given-names></name><name><surname>L&#x000f3;pez-Alomar</surname><given-names>A</given-names></name><name><surname>Vona</surname><given-names>G</given-names></name><name><surname>Moral</surname><given-names>P</given-names></name></person-group><article-title>Classical polymorphisms in Berbers from Moyen Atlas (Morocco): genetics, geography, and historical evidence in the Mediterranean peoples</article-title><source>Ann Hum Biol</source><year>2002</year><volume>29</volume><fpage>473</fpage><lpage>487</lpage><pub-id pub-id-type="pmid">12396367</pub-id><pub-id pub-id-type="doi">10.1080/03014460110104393</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sebetan</surname><given-names>IM</given-names></name></person-group><article-title>a new allele in the alpha-1-antitrypsin system</article-title><source>Hum Hered</source><year>1992</year><volume>42</volume><fpage>206</fpage><lpage>208</lpage><pub-id pub-id-type="pmid">1512004</pub-id><pub-id pub-id-type="doi">10.1159/000154070</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><article-title>American Thoracic Society/European Respiratory Society Statement: Standards for the Diagnosis and Management of Individuals with Alpha-1 Antitrypsin Deficiency</article-title><source>Am J Respir Crit Care Med</source><year>2003</year><volume>168</volume><fpage>818</fpage><lpage>900</lpage><pub-id pub-id-type="pmid">14522813</pub-id><pub-id pub-id-type="doi">10.1164/rccm.168.7.818</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ferrarotti</surname><given-names>I</given-names></name><name><surname>Zorzetto</surname><given-names>M</given-names></name><name><surname>Scabini</surname><given-names>R</given-names></name><name><surname>Mazzola</surname><given-names>P</given-names></name><name><surname>Campo</surname><given-names>I</given-names></name><name><surname>Luisetti</surname><given-names>M</given-names></name></person-group><article-title>A novel method for rapid genotypic identification of alpha1-antitrypsin variants</article-title><source>Diagn Mol Pathol</source><year>2004</year><volume>12</volume><fpage>160</fpage><lpage>163</lpage><pub-id pub-id-type="pmid">15322427</pub-id><pub-id pub-id-type="doi">10.1097/01.pdm.0000128700.22128.80</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zorzetto</surname><given-names>M</given-names></name><name><surname>Russi</surname><given-names>E</given-names></name><name><surname>Senn</surname><given-names>O</given-names></name><name><surname>Imboden</surname><given-names>M</given-names></name><name><surname>Ferrarotti</surname><given-names>I</given-names></name><name><surname>Tinelli</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>SERPINA1 gene variants in individuals from the general population with reduced &#x003b1;1-antitrypsin concentrations</article-title><source>Clin Chem</source><year>2008</year><volume>54</volume><fpage>1331</fpage><lpage>1338</lpage><pub-id pub-id-type="pmid">18515255</pub-id><pub-id pub-id-type="doi">10.1373/clinchem.2007.102798</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ferrarotti</surname><given-names>I</given-names></name><name><surname>Scabini</surname><given-names>R</given-names></name><name><surname>Campo</surname><given-names>I</given-names></name><name><surname>Ottaviani</surname><given-names>S</given-names></name><name><surname>Zorzetto</surname><given-names>M</given-names></name><name><surname>Gorrini</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Laboratory diagnosis of alpha1-antitrypsin deficiency</article-title><source>Transl Res</source><year>2007</year><volume>150</volume><fpage>267</fpage><lpage>274</lpage><pub-id pub-id-type="pmid">17964515</pub-id><pub-id pub-id-type="doi">10.1016/j.trsl.2007.08.001</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gorrini</surname><given-names>M</given-names></name><name><surname>Ferrarotti</surname><given-names>I</given-names></name><name><surname>Lupi</surname><given-names>A</given-names></name><name><surname>Bosoni</surname><given-names>T</given-names></name><name><surname>Mazzola</surname><given-names>P</given-names></name><name><surname>Scabini</surname><given-names>R</given-names></name><etal></etal></person-group><article-title>Validation of a rapid, simple method to measure &#x003b1;1-antitrypsin in human dried blood spots</article-title><source>Clin Chem</source><year>2006</year><volume>52</volume><fpage>899</fpage><lpage>901</lpage><pub-id pub-id-type="pmid">16638961</pub-id><pub-id pub-id-type="doi">10.1373/clinchem.2005.062059</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Orr&#x000f9;</surname><given-names>G</given-names></name><name><surname>Faa</surname><given-names>G</given-names></name><name><surname>Pillai</surname><given-names>S</given-names></name><name><surname>Pilloni</surname><given-names>L</given-names></name><name><surname>Montaldo</surname><given-names>C</given-names></name><name><surname>Pusceddu</surname><given-names>G</given-names></name><etal></etal></person-group><article-title>Rapid PCR real-time genotyping of M-Malton alpha1-antitrypsin deficiency alleles by molecular beacons</article-title><source>Diagn Mol Pathol</source><year>2005</year><volume>14</volume><fpage>237</fpage><lpage>242</lpage><pub-id pub-id-type="pmid">16319694</pub-id><pub-id pub-id-type="doi">10.1097/01.pas.0000178221.44474.b3</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zorzetto</surname><given-names>M</given-names></name><name><surname>Ferrarotti</surname><given-names>I</given-names></name><name><surname>Campo</surname><given-names>I</given-names></name><name><surname>Balestrino</surname><given-names>A</given-names></name><name><surname>Nava</surname><given-names>S</given-names></name><name><surname>Gorrini</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Identification of a novel alpha1-antitrypsin null variant (Q0cairo)</article-title><source>Diagn Mol Pathol</source><year>2005</year><volume>14</volume><fpage>121</fpage><lpage>124</lpage><pub-id pub-id-type="pmid">15905697</pub-id><pub-id pub-id-type="doi">10.1097/01.pas.0000155023.74859.d6</pub-id></citation></ref><ref id="B28"><citation citation-type="other"><person-group person-group-type="author"><name><surname>Jardi</surname><given-names>R</given-names></name><name><surname>Rodriguez</surname><given-names>F</given-names></name><name><surname>Miravitlles</surname><given-names>M</given-names></name><name><surname>Vidal</surname><given-names>R</given-names></name><name><surname>Cotrina</surname><given-names>M</given-names></name><name><surname>Pascual</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>Identification and molecular characterisation of the new alpha-1-antitrypsin deficient allele PI Y<sub>barcelona </sub>(Asp<sup>256</sup>&#x02192;Val and Pro<sup>391</sup>&#x02192;His)</article-title><source>Hum Mutation #174 1-6 (1998) Online</source></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Faber</surname><given-names>JP</given-names></name><name><surname>Poller</surname><given-names>W</given-names></name><name><surname>Weidinger</surname><given-names>S</given-names></name><name><surname>Kirchgesser</surname><given-names>M</given-names></name><name><surname>Schwaab</surname><given-names>R</given-names></name><name><surname>Olek</surname><given-names>K</given-names></name></person-group><article-title>Sequence data of fifteen new &#x003b1;1-antitrypsin variants including two PI*Q0 and one deficient PI*M allele</article-title><source>Am J Hum Genet</source><year>1994</year><volume>55</volume><fpage>1113</fpage><lpage>1121</lpage><pub-id pub-id-type="pmid">7977369</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jardi</surname><given-names>R</given-names></name><name><surname>Rodriguez</surname><given-names>F</given-names></name><name><surname>Lopez-Talavera</surname><given-names>JC</given-names></name><name><surname>Miravitlles</surname><given-names>M</given-names></name><name><surname>Cotrina</surname><given-names>M</given-names></name><name><surname>Costa</surname><given-names>X</given-names></name><etal></etal></person-group><article-title>Characterization of the New Alpha-1-Antitrypsin-Deficient PI M-Type Allele, PI M<sub>vall d'hebron </sub>(Pro<sup>369</sup>&#x02192;Ser)</article-title><source>Hum Hered</source><year>2000</year><volume>50</volume><fpage>320</fpage><lpage>321</lpage><pub-id pub-id-type="pmid">10878477</pub-id><pub-id pub-id-type="doi">10.1159/000022935</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hersh</surname><given-names>CP</given-names></name><name><surname>Dahl</surname><given-names>M</given-names></name><name><surname>Ly</surname><given-names>NP</given-names></name><name><surname>Berkey</surname><given-names>CS</given-names></name><name><surname>Nordestgaard</surname><given-names>BG</given-names></name><name><surname>Silverman</surname><given-names>EK</given-names></name></person-group><article-title>Chronic obstructive pulmonary disease in a1-antitrypsin PI MZ heterozygotes: a meta-analysis</article-title><source>Thorax</source><year>2004</year><volume>59</volume><fpage>843</fpage><lpage>849</lpage><pub-id pub-id-type="pmid">15454649</pub-id><pub-id pub-id-type="doi">10.1136/thx.2004.022541</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ferrarotti</surname><given-names>I</given-names></name><name><surname>Gorrini</surname><given-names>M</given-names></name><name><surname>Scabini</surname><given-names>I</given-names></name><name><surname>Ottaviani</surname><given-names>S</given-names></name><name><surname>Mazzola</surname><given-names>P</given-names></name><name><surname>Campo</surname><given-names>I</given-names></name><etal></etal></person-group><article-title>Secondary outputs of alpha1-antitrypsin deficiency targeted detection programme</article-title><source>Respir Med</source><year>2008</year><volume>102</volume><fpage>354</fpage><lpage>358</lpage><pub-id pub-id-type="pmid">18396513</pub-id><pub-id pub-id-type="doi">10.1016/j.rmed.2007.10.015</pub-id></citation></ref></ref-list></back></article> 